Evidation has promoted its president and chief operating officer, Leslie Oley Wilberforce, to be its next CEO, as the real-world health data company forms new partnerships for its research platform.
Wilberforce will take the helm from co-founder Christine Lemke, who will stay on at Evidation as an advisor and member of the board.
Leslie Oley Wilberforce Evidation
Leslie Oley Wilberforce (Evidation)
During her time as COO, Wilberforce helped the former Fierce Medtech Fierce 15 winner establish its research platform as an enterprise product such as through collaborations with the Michael J. Fox Foundation to explore digital biomarkers for Parkinson’s disease as well as with the Our Future Health Initiative at the U.K. National Health Service, which plans to enroll up to 5 million participants.
Alongside Wilberforce's appointment, Evidation also announced it will work with the American Heart Association to support its Research Goes Red program—an effort focused on signing up more women to participate in cardiovascular studies to better understand those diseases’ unique impacts.
Related
Evidation launches digital migraine research platform and symptom tracker
“Leslie is a driven leader whose operational prowess and people-first leadership approach has made her an indispensable force behind Evidation’s success and the right leader for this moment,” Lemke said in a statement. “She has played a defining role in our growth, and I have full confidence she’ll propel Evidation to even greater impact in the years ahead.”
Before joining Evidation in 2015, Wilberforce previously helped lead product strategy and commercialization efforts at Boston Scientific, ApniCure and Voyage Medical.
Last fall, Evidation also brought on Phil Johnson to serve as chief commercial officer and support its push toward more partnerships. Formerly a VP at Tempus, Johnson helped steer clinical diversity and innovation, life sciences and platform services. Before that he was a healthcare and life sciences leader at Amazon Web Services.